SCHEMBL10292839

SCHEMBL10292839

CCc1nc2c(c(OC(C)C)c(C(=O)Nc3cccc(F)c3)n2C)c(=O)n1Cc1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGES O14684 4/20 0.46
▸ KMT2A Q03164 2/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ GAA P10253 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ PDE6D O43924 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ PTGER3 P43115 1/20 0.38
▸ PTGER1 P34995 1/20 0.37
▸ POLB P06746 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ P2RX3 P56373 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11990835 0.93 PTGES (0.46) PTGESKMT2AALDH1A1NPSR1KDM4E
SCHEMBL10003686 0.92 PTGES (0.48) PTGESKMT2AALDH1A1NPSR1KDM4E
SCHEMBL11990834 0.89 PTGES (0.46) PTGESKMT2AALDH1A1NPSR1MAPT
SCHEMBL10292840 0.89 PTGES (0.43) PTGESKMT2AALDH1A1NPSR1KDM4E
SCHEMBL10292461 0.89 KMT2A (0.43) PTGESKMT2AALDH1A1NPSR1KDM4E
SCHEMBL10292550 0.86 KMT2A (0.43) PTGESKMT2AALDH1A1NPSR1GAA
SCHEMBL10004586 0.85 KMT2A (0.48) PTGESKMT2AALDH1A1NPSR1HPGD
SCHEMBL10292542 0.85 KMT2A (0.44) PTGESKMT2AALDH1A1NPSR1HPGD
SCHEMBL11990855 0.85 KMT2A (0.47) PTGESKMT2AALDH1A1NPSR1HPGD
SCHEMBL11990856 0.85 KMT2A (0.43) PTGESKMT2AALDH1A1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471793-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-10-05 — — EP disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
EP-2471793-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH PTGES 1468/4885KMT2A 423/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback